What Are the Chances of Getting Shingles After the Vaccine?

Getting both doses of the recombinant shingles vaccine (Shingrix) reduces your risk of developing shingles by roughly 70 to 85 percent in everyday medical practice, depending on the study and population. In clinical trials, the numbers looked even better, with efficacy above 97 percent across age groups. That gap between tightly controlled trials and real-world conditions is worth understanding, because it shapes your actual odds. The short version: vaccination makes shingles far less likely and, if it does break through, far less severe, but it does not make the risk zero.

Trial Numbers Versus What Happens in Practice

In the pivotal clinical trial published in the New England Journal of Medicine, the recombinant zoster vaccine showed overall efficacy against shingles of about 97 percent in adults 50 and older, with protection holding between roughly 97 and 98 percent across all age subgroups studied.¹ That is an extraordinary result, and it’s what earned the vaccine its reputation. But clinical trials enroll carefully selected participants who receive both doses on schedule under close monitoring. Real life is messier.

When researchers looked at how the vaccine performed across millions of people in routine medical care in the United States, effectiveness after two doses settled around 70 to 76 percent against shingles overall.² Another large U.S. claims-based study found two-dose effectiveness of about 70 percent.³ A Japanese study using clinical databases found 85 percent effectiveness, with only 2 out of 612 vaccinated patients developing shingles compared to 13 out of 612 matched unvaccinated patients.⁴

Why the spread? Real-world populations include people with weaker immune systems, chronic illnesses, and delayed or incomplete dosing schedules. These factors pull the headline number down. But even at the lower end of this range, your chance of getting shingles after vaccination drops dramatically. If roughly 1 in 3 unvaccinated adults will develop shingles in their lifetime, cutting that risk by 70 percent or more is a meaningful shift in your odds.

One Dose Is Not Enough

The shingles vaccine is a two-dose series, and the difference between one dose and two is substantial. In the large real-world U.S. study, one dose provided about 64 percent effectiveness in the first year, but that dropped to around 45 percent by the second year and hovered near 48 to 52 percent afterward.² Two doses held steadier: about 79 percent in the first year, 75 percent in the second, and 73 percent in years three and four.

This matters because a fair number of people get the first shot and never return for the second, often because the vaccine can cause a couple of uncomfortable days of arm soreness, fatigue, and muscle aches. That reaction is the immune system responding to a potent adjuvant in the vaccine. If you stopped at one dose, you got some protection, but significantly less than the full course provides, and it fades faster. The second dose is what locks in the durable immune memory.

How Long Does Protection Last?

This is one of the most practically important questions, and the data keep getting better. The longest follow-up trial now extends out to 11 years after vaccination. In that final analysis, vaccine efficacy against shingles was sustained at about 82 percent in the eleventh year for people who were 50 or older at the time of vaccination, with an overall efficacy of roughly 88 percent across the full follow-up period.⁵ Protection against postherpetic neuralgia, the debilitating nerve pain that can linger for months or years after a shingles rash clears, was even higher at about 88 percent.

Immune measurements help explain this durability. Antibody levels against the key viral protein remained over five times higher than pre-vaccination levels at the 10-year mark, and the specialized immune cells the body needs to keep the virus in check stayed well above baseline too.⁶ These immune markers plateaued rather than continuing to fall, which is a good sign that protection could extend well beyond the current data window.

Still, there is some decline over time. The evidence is clear that protection remains high, but researchers and public health authorities continue to assess whether a booster dose will eventually be needed.⁷ As of now, no booster is recommended. If you received both doses years ago, your protection is very likely still strong.

What Happens If You Get Shingles Despite Being Vaccinated

Breakthrough shingles does happen, and knowing what to expect is useful. The good news is that these cases tend to be milder, shorter, and less likely to cause the complications people fear most. Among vaccinated people who did develop shingles, the risk of postherpetic neuralgia was about 47 percent lower than in unvaccinated people who got shingles.⁸ That means the vaccine works on two levels: it prevents most shingles outbreaks entirely, and when it does not prevent an outbreak, it reduces the chance that outbreak will cause the worst long-term consequences.

Postherpetic neuralgia is the complication most people worry about, and for good reason. It can cause burning, stabbing nerve pain that persists for months after the rash heals, sometimes becoming chronic and resistant to treatment. In the 11-year follow-up data, the vaccine maintained roughly 88 percent efficacy against postherpetic neuralgia and over 90 percent efficacy against other shingles-related complications.⁵ Even if the vaccine’s overall shingles prevention dips slightly over time, its protection against the most disabling outcomes stays especially strong.

A Counterintuitive Finding Right After the First Dose

One recent finding surprised researchers and may concern people who have just received their first shot. A self-controlled case-series analysis in the UK found that adults 65 and older had a substantially elevated rate of shingles presentations within the first 21 days after dose 1.⁹ The increase was about 11-fold in that short window, which sounds alarming out of context. But the key word is “transient.” This effect was not seen in younger adults, and it was not seen after dose 2.

The likely explanation is that the strong immune activation triggered by the vaccine can, in some older adults whose immune surveillance of the latent virus was already weakening, transiently disrupt the balance keeping the virus dormant. Essentially, the immune system’s sudden pivot toward building new defenses may briefly open a window where the virus can reactivate. After two doses, the opposite happened: recipients had a 73 percent reduction in shingles compared to their own baseline risk periods. Postherpetic neuralgia risk was not increased at any point after vaccination. This finding reinforces, rather than undermines, the importance of completing the two-dose series.

Why Age Matters Less Than You Might Think

One of the most common concerns about shingles vaccination is whether it works well enough in people who are quite old, since shingles risk climbs steeply with age and the immune system weakens over time. The data on this point are reassuring. In the original clinical trial, efficacy was between about 97 and 98 percent across all age groups studied, with no meaningful dropoff in people 70 and older.¹

In real-world data, the story is similar. One large study found that two-dose effectiveness was not significantly lower for people over 80 compared to younger recipients.³ The Japanese cohort study found effectiveness was the same regardless of age.⁴ The 11-year follow-up trial showed slightly lower efficacy in people 70 and older at initial vaccination (about 73 percent versus 80 percent for those 50 and older during the long-term follow-up period), but protection remained substantial.⁵

This is a notable feature of the recombinant vaccine. An earlier live-attenuated shingles vaccine (now discontinued in the U.S.) lost effectiveness markedly in older recipients and faded much more quickly. The current vaccine’s adjuvant system drives a robust immune response even in people whose immune systems are less responsive to ordinary stimulation.¹⁰ This is one of the main reasons it replaced the older vaccine.

People With Weakened Immune Systems

If you take immunosuppressive medications or have a condition that dampens your immune system, shingles risk is higher than average, and the question of vaccine effectiveness becomes more personal. The real-world evidence offers some reassurance. In one large study, the vaccine was effective in people with immunosuppressive conditions, and two-dose effectiveness was not significantly reduced in people with autoimmune conditions.³ In another study, people who received corticosteroids before vaccination still had about 65 percent effectiveness, compared to 77 percent in those who did not.²

Because the recombinant vaccine does not contain live virus, it can be given to people who could not safely receive the older live vaccine, including transplant recipients, people on certain biologic therapies, and others with significantly compromised immunity. The protection level in these groups may be lower than in healthy adults, but the baseline risk of shingles is also much higher, so the absolute benefit of vaccination can actually be greater.

Why the Virus Breaks Through at All

Shingles is caused by the reactivation of varicella-zoster virus, the same virus that causes chickenpox. After your initial chickenpox infection, the virus retreats into nerve cell clusters along the spine and skull, where it can sit dormant for decades. The immune system, particularly specialized T cells, keeps it in check. When that surveillance weakens, whether from aging, stress, illness, or immune-suppressing drugs, the virus can reactivate and travel along a nerve to the skin, producing the characteristic painful, blistered rash.¹¹

The vaccine works by training the immune system to recognize a key protein on the virus’s surface, using a potent adjuvant to amplify both the antibody and T-cell responses. Studies comparing immune responses between the recombinant vaccine and the older live vaccine found that the recombinant version produced stronger and more persistent memory T-cell responses, which are the cells most directly responsible for keeping the virus dormant.¹² But no vaccine can permanently restore the immune system to the level of a young adult. Over time, immune responses do slowly decline, and the virus is never truly eliminated from the body. It is always there, waiting for a moment of vulnerability. This is why breakthrough cases happen and why long-term monitoring of vaccine durability is so important.

Getting the Shingles Vaccine Alongside Other Shots

A practical concern for many people is whether you can get the shingles vaccine at the same appointment as a flu shot or another routine vaccine. The evidence says yes. Clinical trials and post-market surveillance data have found that giving the recombinant zoster vaccine alongside inactivated influenza vaccines does not meaningfully change the side-effect profile, the immune response, or the safety of either vaccine.¹³ This is useful information given that many people eligible for the shingles vaccine are also getting annual flu shots, pneumococcal vaccines, COVID boosters, and other immunizations. You do not need to space them out weeks apart.

One thing worth keeping in mind: the shingles vaccine is known for producing more noticeable short-term side effects than many other adult vaccines. Arm soreness, fatigue, headache, and sometimes low-grade fever are common for a day or two. If you are getting it alongside another vaccine, you may feel rougher than you would from either shot alone, but this does not indicate a safety problem. It reflects the strong adjuvant doing its job.

When Vaccination Makes the Biggest Difference at a Population Level

From a public health standpoint, the question of who to vaccinate first is partly about math. A modeling study evaluating expanded age eligibility in England found that vaccinating people in their 60s was the most efficient strategy for preventing quality-of-life losses, because that age group combines moderately high shingles risk with many remaining years to benefit from protection. Meanwhile, vaccinating people in their 80s was the most efficient strategy for reducing hospitalization costs, because shingles complications in very old adults are more likely to require inpatient care.¹⁴

For you personally, the calculation is simpler. If you are 50 or older and have not been vaccinated, the odds strongly favor getting it. If you already had shingles in the past, vaccination still reduces the risk of a recurrence. If you received the older live vaccine (Zostavax) years ago, you are still recommended to get the current recombinant vaccine, since the older version offered weaker and shorter-lived protection. The question in the title has a genuinely encouraging answer: after completing the two-dose series, your chances of getting shingles are substantially lower than they would otherwise be, and the protection lasts for at least a decade with only modest decline.

1
PubMed. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
2
PubMed Central. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting
3
PubMed. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
4
PubMed Central. Real-world effectiveness of recombinant herpes Zoster vaccine: a retrospective, cohort study in Japan
5
PubMed Central. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications
6
PubMed Central. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
7
PubMed. Cost-Effectiveness of Recombinant Zoster Vaccine (Shingrix) in US Adults Aged ≥50 Years
8
JAMA Network Open. Recombinant Zoster Vaccination and Risk of Postherpetic Neuralgia or Zoster Ophthalmicus
9
PubMed Central. Transient Increased Risk of Shingles Post–Shingrix Vaccination: Self-Controlled Case-Series Analysis
10
PubMed Central. Immune responses to zoster vaccines
11
Journal of Bacteriology and Virology. Immune Responses to Varicella Zoster Virus and Effective Vaccines
12
The Journal of Immunology. A comparison of the immunogenicity of a live attenuated herpes zoster vaccine (ZV) and the recombinant gE/AS01B candidate vaccine in older adults
13
PubMed Central. The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018–2024
14
PubMed. The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England